MAP3K1 and inflammatory bowel disease: This showed that the MAPK signaling pathway in the intestinal mucosal of experimental UC mice is activated, whereas intragastric administration of CGMP at 50 mg/kg bw•d significantly reduced the expression of MEKK1, and this inhibitory effect was similar to that of SASP, a medicine used to treat IBD.